-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Reneo Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q2 2024.
- Reneo Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$6.36M, a 69.8% increase year-over-year.
- Reneo Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$61.8M, a 5.71% increase year-over-year.
- Reneo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$83.1M, a 54.2% decline from 2022.
- Reneo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$53.8M, a 35.2% decline from 2021.
- Reneo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$39.8M, a 104% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)